Enitociclib is synergistic with anti-MM chemotherapies. Three-dimensional (3D) response surface plots for combinatory activity of enitociclib with bortezomib, lenalidomide, pomalidomide, or venetoclax treated in MM cell lines for 96 hours. Cell viability was measured by Alamar Blue assay. Percent cell viability was normalized to corresponding treatment with DMSO (vehicle control). Synergy score is calculated by SynergyFinder based on the ZIP interaction model.⁷ Red indicates synergism, and green indicates antagonism of the respective drug combinations. Maximal synergistic effects (MSEs) are indicated when the synergy score is >10, and the drug concentrations at which the MSE occurs are highlighted in yellow.